6533b7d8fe1ef96bd126adc6
RESEARCH PRODUCT
Initial Clinical Experience Using the Low-Profile Altura Endograft System With Double D-Shaped Proximal Stents for Endovascular Aneurysm Repair.
Janis SavlovskisE. Sebastian DebusDainis KrievinsAlbrecht KramerGeorgij OszkinisChristopher K. ZarinsAlexander Oberhubersubject
Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyProsthesis DesignEndovascular aneurysm repairRisk Assessment03 medical and health sciencesBlood Vessel Prosthesis Implantation0302 clinical medicinePostoperative ComplicationsRisk FactorsmedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionAdverse effectStrokeAgedAged 80 and overbusiness.industryPatient SelectionEndovascular ProceduresMiddle Agedmedicine.diseaseThrombosisAbdominal aortic aneurysmSurgeryBlood Vessel ProsthesisProsthesis FailureTreatment OutcomeRespiratory failureSurgeryFemaleStentsCardiology and Cardiovascular MedicineParaplegiabusinessAortic Aneurysm Abdominaldescription
Purpose: To report the initial clinical results of endovascular aneurysm repair (EVAR) using the low-profile (14-F) Altura Endograft System, which features a double “D-shaped” stent design with suprarenal fixation and modular iliac components that are deployed from distal to proximal. Methods: From 2011 to 2015, 90 patients (mean age 72.8±8.3 years; 79 men) with abdominal aortic aneurysm (AAA; mean diameter 53.8±5.7 mm) were treated at 10 clinical sites in 2 prospective, controlled clinical studies using the Altura endograft. Outcomes evaluated included mortality, major adverse events (MAEs: all-cause death, stroke, paraplegia, myocardial infarction, respiratory failure, bowel ischemia, and blood loss ≥1000 mL), and clinical success (freedom from procedure-related death, type I/III endoleak, migration, thrombosis, and reintervention). Results: Endografts were successfully implanted in 89 (99%) patients; the single failure was due to delivery system malfunction before insertion in the early-generation device. One (1%) patient died and 4 patients underwent reinterventions (1 type I endoleak, 2 iliac limb stenoses, and 1 endograft occlusion) within the first 30 days. During a median follow-up of 12.5 months (range 11.5–50.9), there were no aneurysm ruptures, surgical conversions, or AAA-related deaths. The cumulative MAE rates were 3% (3/89) at 6 months and 7% (6/89) at 1 year. Two patients underwent coil embolization of type II endoleaks at 6.5 months and 2.2 years, respectively. Clinical success was 94% (84/89) at 30 days, 98% (85/87) at 6 months, and 99% (82/83) at 1 year. Conclusion: Early results suggest that properly selected AAA patients can be safely treated using the Altura Endograft System with favorable midterm outcome. Thus, further clinical investigation is warranted to evaluate the role of this device in the treatment of AAA.
year | journal | country | edition | language |
---|---|---|---|---|
2018-04-20 | Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists |